abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
01 juin 2022 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, June 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...